Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

OBJECTIVE: Metabolic activation of the innate immune system governed by interleukin (IL)-1β contributes to β-cell failure in type 2 diabetes. Gevokizumab is a novel, human-engineered monoclonal anti–IL-1β antibody. We evaluated the safety and biological activity of gevokizumab in patients with type...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavelti-Weder, Claudia, Babians-Brunner, Andrea, Keller, Cornelia, Stahel, Marc A., Kurz-Levin, Malaika, Zayed, Hany, Solinger, Alan M., Mandrup-Poulsen, Thomas, Dinarello, Charles A., Donath, Marc Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402269/
https://www.ncbi.nlm.nih.gov/pubmed/22699287
http://dx.doi.org/10.2337/dc11-2219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402269/
https://www.ncbi.nlm.nih.gov/pubmed/22699287
http://dx.doi.org/10.2337/dc11-2219

Ejemplares similares